UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000048834
Receipt No. R000055631
Scientific Title Effects of SGLT2 inhibitor on gut microbiota in the patients with type 2 diabetes
Date of disclosure of the study information 2022/09/02
Last modified on 2022/09/02 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of SGLT2 inhibitor on gut microbiota in the patients with type 2 diabetes
Acronym Effects of SGLT2 inhibitor on gut microbiota in the patients with type 2 diabetes
Scientific Title Effects of SGLT2 inhibitor on gut microbiota in the patients with type 2 diabetes
Scientific Title:Acronym Effects of SGLT2 inhibitor on gut microbiota in the patients with type 2 diabetes
Region
Japan

Condition
Condition Type 2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the effects of treatment of SGLT2 inhibitor for 3 months on gut microbiota in the patients with type 2 diabetes
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Fecal microbiota
Key secondary outcomes Body weight and hemoglobin A1c level

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 The patients with type 2 diabetes are treated with 2.5 mg/day luseogliflozin or 5 mg/day dapagliflozin for 3 months
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
30 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria Hemoglobin A1c level: 6.5-11.5%
Key exclusion criteria eGFR: less than 45 mL/min/1.73 m2
Target sample size 10

Research contact person
Name of lead principal investigator
1st name Masataka
Middle name
Last name Kusunoki
Organization Nagoya University
Division name Research Center of Health, Physical Fitness and Sports
Zip code 464-8601
Address Furo-cho, Chikusa-ku, Nagoya
TEL 052-789-3946
Email info@tonyo.jp

Public contact
Name of contact person
1st name Masataka
Middle name
Last name Kusunoki
Organization Nagoya University
Division name Research Center of Health, Physical Fitness and Sports
Zip code 464-8601
Address Furo-cho, Chikusa-ku, Nagoya
TEL 052-789-3946
Homepage URL
Email info@tonyo.jp

Sponsor
Institute Akishima Clinic
Institute
Department

Funding Source
Organization Akishima Clinic
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Akishi
Address 4-2-29 Sakae, Naka-ku, Naogya
Tel 052-243-1024
Email info@tonyo.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人社団織田会あきしまクリニック(愛知県)

Other administrative information
Date of disclosure of the study information
2022 Year 09 Month 02 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 8
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 07 Month 29 Day
Date of IRB
2019 Year 09 Month 22 Day
Anticipated trial start date
2019 Year 10 Month 14 Day
Last follow-up date
2022 Year 04 Month 30 Day
Date of closure to data entry
2022 Year 07 Month 31 Day
Date trial data considered complete
2022 Year 08 Month 31 Day
Date analysis concluded
2022 Year 12 Month 20 Day

Other
Other related information

Management information
Registered date
2022 Year 09 Month 02 Day
Last modified on
2022 Year 09 Month 02 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055631